eIF4E-IN-1

• UNSPSC Description:

  eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y)[1].

• Target Antigen:

  Eukaryotic Initiation Factor (eIF)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/eif4e-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N#CC1=C(N2CCN(CC2)C)C(C(F)(F)F)=CC3=C1C(N(CCOC4=CC=C(C=C4C5=C(SC=C6C(O)=O)C6=NC(C)=C5)Cl)C(C)=N3)=O

• Molecular Weight:

  697.13

• References & Citations:

  [1]Kevin R, et al. Eif4e inhibitors for use as immune checkpoint modulators and related methods. Patent WO2021003194A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2573979-31-2